Weekly vs. Every 2 Week vs. Every 3 Week Administration of ABI-007 (Abraxane)/Bevacizumab Combination in Metastatic Breast Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
40 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Metropolitan Oncology Center
San Juan, Puerto Rico
- Division of Hematology/oncology University of Alabama at Birmingham
Birmingham, Alabama, United States
- Little Rock Hematology Oncology Associates
Little Rock, Arkansas, United States
- California Oncology of the Central Valley
Fresno, California, United States
- Glendale Memorial Hospital & Health Center
Glendale, California, United States
- Front Range Cancer Specialists
Fort Collins, Colorado, United States
- Oncology Associates of Bridgeport
Bridgeport, Connecticut, United States
- Palm Beach Institute of Hematology and Oncology
Boynton Beach, Florida, United States
- Memorial Cancer Institute/breast Cancer Center
Hollywood, Florida, United States
- Florida Cancer Institute
Hudson, Florida, United States
- Hematology Oncology Associates
Lake Worth, Florida, United States
- Medical Specialist of the Palm Beaches, Inc
Lake Worth, Florida, United States
- Gulfcoast Oncology Associates
St. Petersburg, Florida, United States
- Peachtree Hematology & Oncology Associates
Atlanta, Georgia, United States
- Northwest Georgia Oncology Centers, Pc
Marietta, Georgia, United States
- Center of Hope for Cancers and Blood
Stockbridge, Georgia, United States
- Maine Center for Cancer Medicine & Blood Disorders
Scarborough, Maine, United States
- Greater Baltimore Medical Center
Baltimore, Maryland, United States
- Harbor View Cancer Center
Baltimore, Maryland, United States
- Boston Medical Center Moakley Building, Solomont Center for Hematology & Medical Oncology
Boston, Massachusetts, United States
- North Shore Medical Cancer Center
Peabody, Massachusetts, United States
- St. John'S Mercy Medical Center
St Louis, Missouri, United States
- Nebraska Methodist Hospital
Omaha, Nebraska, United States
- Drs. Forte, Schleidere, & Attas, Pa
Englewood, New Jersey, United States
- Saint Barnabas Medical Center
Livingston, New Jersey, United States
- Monmouth Medical Center
Long Branch, New Jersey, United States
- Rosewell Park Cancer Institute Elm & Carlton Carlton Building
Buffalo, New York, United States
- Beth Israel Comprehensive Cancer Center
New York, New York, United States
- Memorial Sloan Kettering Cancer Center
New York, New York, United States
- Nyu Clinical Cancer Center
New York, New York, United States
- Marion L. Shepard Cancer Center
Washington, North Carolina, United States
- Medical Oncology Aultman Hospital
Canton, Ohio, United States
- Cancer Centers of Southwest Oklahoma Research
Lawton, Oklahoma, United States
- Abington Hematology Oncology
Willow Grove, Pennsylvania, United States
- Family Cancer Center
Collierville, Tennessee, United States
- Tennessee Cancer Specialists
Knoxville, Tennessee, United States
- Tx Oncology, Pa
Austin, Texas, United States
- South Texas Oncology & Hematology Clinical Research Dept.
San Antonio, Texas, United States
- Virginia Commonwealth University Medical Oncology
Richmond, Virginia, United States
- Swedish Cancer Institute
Seattle, Washington, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 1 Feb 2006
- Primary completion
- 1 Jul 2010
- Completion
- 1 Mar 2011
- Last update posted
- 22 Nov 2019
- Registered enrollment
- 208
- Registry id
- NCT00281528
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.